v3.26.1
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Cash flows from operating activities:    
Net income (loss) $ (23,849) $ 30,297
Adjustments to reconcile net income (loss) to net cash used in operating activities:    
Depreciation and amortization expense 2,500 2,263
Stock-based compensation expense 4,712 4,701
Provision for inventory obsolescence 202 209
Net amortization of premiums and accretion of discounts on marketable securities 221 (385)
Loss on disposal of property and equipment 12 95
Gain on sale of Desktop Portfolio, net of transaction costs   (56,200)
Provision for credit losses (57) 28
Change in fair value of contingent consideration 12,823 9,291
Amortization of debt issuance costs 25  
Deferred tax liabilities (54)  
Changes in operating assets and liabilities, net of business combinations:    
Accounts receivable, net 419 5,327
Inventory (1,358) (5,153)
Prepaid expenses and other current assets 4,242 (3,317)
Other long-term assets (156) 181
Accounts payable and accrued expenses 3,410 (5,641)
Deferred revenue 1,241 (2,436)
Right-of-use operating lease assets 388 1,421
Operating lease liabilities (345) (1,484)
Net cash provided by (used in) operating activities 4,376 (20,803)
Cash flows from investing activities:    
Purchases of property and equipment (202) (281)
Purchases of marketable securities (23,350) (59,417)
Acquisition of businesses, net of cash acquired (12,721)  
Proceeds from sale of Desktop Portfolio   69,917
Proceeds from maturities of marketable securities 26,964 28,507
Net cash provided by (used in) investing activities (9,309) 38,726
Cash flows from financing activities:    
Payments for withholding taxes on vested awards (2,344) (655)
Proceeds from issuance of common stock 1,262 388
Payment of deferred financing costs (121)  
Net cash used in financing activities (1,203) (267)
Effect of foreign exchange rate changes on cash and cash equivalents (56) 27
Net increase (decrease) in cash, cash equivalents and restricted cash (6,192) 17,683
Cash, cash equivalents and restricted cash at beginning of period 70,592 44,203
Cash, cash equivalents and restricted cash at end of period 64,400 61,886
Supplemental disclosure of noncash investing and financing information:    
Property and equipment included in account payable 17 169
Transfers of inventory to property and equipment 828 $ 238
Fair value of common stock issued for acquisition of NIRLAB $ 1,726